Mark Laughlin
Roche (United States) · 11 works · 1,461 citations · h-index 9
Top works
- A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C
- Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
- A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)
- Interferon Alfa-2b in Combination With Ribavirin for the Treatment of Chronic Hepatitis C in Children: Efficacy, Safety, and Pharmacokinetics *
- Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic‐pharmacodynamic models
- Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFNα: results from the Primoferon A (ANRS 086) Study
- A Double-Blind Placebo-Controlled Trial of Single-Dose Intravaginal versus Single-Dose Oral Metronidazole in the Treatment of Trichomonal Vaginitis
- 1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN
- A DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF ORAL VERSUS VAGINAL METRONIDAZOLE FOR THE TREATMENT OF TRICHOMONAL VAGINITIS
- 749 EARLY ON-TREATMENT RESPONSES DURING PEGYLATED IFN PLUS RIBAVIRIN ARE INCREASED FOLLOWING 13 DAYS OF COMBINATION NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITOR THERAPY (INFORM-1)
- Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection